The ABL and JAK Tyrosine Kinase Pathways Are Co-Activated in BCR/ABL1 Positive Acute Lymphoblastic Leukemia

被引：0
|
作者：
Bhagavathi, S. [1 ]
Aviv, H. [1 ]
机构：
[1] Rutgers State Univ, New Brunswick, NJ USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2016年 / 18卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H30
引用
收藏
页码：958 / 958
页数：1
相关论文
共 50 条
  • [21] Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
    Zuna, Jan
    Hovorkova, Lenka
    Krotka, Justina
    Winkowska, Lucie
    Novak, Zbynek
    Sramkova, Lucie
    Stary, Jan
    Trka, Jan
    Cazzaniga, Giovanni
    Cario, Gunnar
    Zaliova, Marketa
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : E269 - E271
  • [22] Entire ABL1 Gene Deletion Without BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute Lymphoblastic Leukemia
    Jiang, Yijing
    Zhang, Jie
    Guo, Dan
    Zhang, Chenlu
    Hong, Lemin
    Huang, Hongming
    Liu, Haiyan
    ONCOTARGETS AND THERAPY, 2020, 13 : 783 - 790
  • [23] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [24] Adverse drug reactions reported with BCR/ABL1 tyrosine kinase inhibitors
    Tournaire, G.
    Despas, F.
    Rousseau, V.
    Montastruc, J. L.
    Bondon-Guitton, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 47 - 47
  • [25] MicroRNA signature in BCR-ABL1-like and BCR-ABL1-positive childhood acute lymphoblastic leukemia: similarities and dissimilarities
    Moqadam, Farhad Akbari
    Lange-Turenhout, Ellen A. M.
    van der Veer, Arian
    Marchante, Joao R. M.
    Boer, Judith M.
    Pieters, Rob
    den Boer, Monique
    LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1942 - 1945
  • [26] Detection of ABL1 kinase Domain Mutations in Therapy Naive BCR-ABL1 Positive ALL
    Baer, Constance Regina
    Meggendorfer, Manja
    Haferlach, Claudia
    Kern, Wolfgang
    Haferlach, Torsten
    BLOOD, 2017, 130
  • [27] Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist?
    Nacheva, Ellie P.
    Grace, Colin D.
    Brazma, Diana
    Gancheva, Katya
    Howard-Reeves, Julie
    Rai, Lena
    Gale, Rosemary E.
    Linch, David C.
    Hills, Robert K.
    Russell, Nigel
    Burnett, Alan K.
    Kottaridis, Panagiotis D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (04) : 541 - 550
  • [28] The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
    Thomas, Xavier
    Heiblig, Mael
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1061 - 1070
  • [29] Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Eide, Christopher A.
    Bottomly, Daniel
    Savage, Samantha L.
    White, Libbey
    Wilmot, Beth
    Schultz, Anna M. Reister
    Uchida, Kimberly A.
    Agarwal, Anupriya
    Traer, Elie
    Beppu, Lan
    Sala-Torra, Olga
    Radich, Jerald P.
    Eickelberg, Garrett
    Press, Richard D.
    Loriaux, Marc M.
    Tantravahi, Srinivas K.
    Pomicter, Anthony D.
    Zabriskie, Matthew S.
    Deininger, Michael W.
    O'Hare, Thomas
    Tyner, Jeffrey W.
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    BLOOD, 2016, 128 (22)
  • [30] Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Kitahara, Toshihiko
    Tanaka, Yoko
    Ohyashiki, Kazuma
    PLOS ONE, 2014, 9 (02):
12345